Humana (NYSE:HUM) Shares Gap Down – Time to Sell?

Humana Inc. (NYSE:HUM) shares gapped down before the market opened on Monday . The stock had previously closed at $288.12, but opened at $273.00. Humana shares last traded at $276.77, with a volume of 561,661 shares trading hands.

Analyst Ratings Changes

A number of analysts recently weighed in on HUM shares. TD Cowen upped their price objective on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Piper Sandler lowered shares of Humana from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $392.00 to $274.00 in a research note on Thursday, October 3rd. Stephens reaffirmed an “equal weight” rating and issued a $250.00 price objective on shares of Humana in a research note on Wednesday, October 9th. UBS Group lowered their price objective on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, October 4th. Finally, Truist Financial lowered their price objective on shares of Humana from $400.00 to $260.00 and set a “hold” rating for the company in a research note on Friday, October 11th. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $315.86.

Humana Stock Down 0.8 %

The company’s 50-day moving average is $286.27 and its 200 day moving average is $332.44. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $33.72 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 2.23 and a beta of 0.52.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. As a group, analysts anticipate that Humana Inc. will post 15.83 EPS for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.26%. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Hedge Funds Weigh In On Humana

Hedge funds and other institutional investors have recently bought and sold shares of the business. Swedbank AB grew its stake in shares of Humana by 3.0% during the 3rd quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock worth $33,567,000 after purchasing an additional 3,085 shares during the period. Heritage Oak Wealth Advisors LLC acquired a new stake in shares of Humana during the 2nd quarter worth approximately $3,456,000. Mandatum Life Insurance Co Ltd grew its stake in shares of Humana by 115.4% during the 3rd quarter. Mandatum Life Insurance Co Ltd now owns 14,000 shares of the insurance provider’s stock worth $4,434,000 after purchasing an additional 7,500 shares during the period. APG Asset Management US Inc. lifted its position in shares of Humana by 3.0% during the 2nd quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock valued at $25,274,000 after buying an additional 1,955 shares in the last quarter. Finally, Sei Investments Co. lifted its position in shares of Humana by 0.4% during the 1st quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock valued at $21,462,000 after buying an additional 264 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.